45. The pharmaceutical composition of claim 42 further comprising an additive from the group consisting of water, a stabilizer, and a protein aggregation controller.

46. The pharmaceutical composition of claim 42 wherein the molar ratio of the therapeutically compound : plasma protein is within the range of 1 : 0.05 to 1 : 100.

47. The pharmaceutical composition of claim 45 wherein the molar ratio of the therapeutically compound : plasma protein is within the range of 1 : 0.1 to 1 :50.

48. The pharmaceutical composition of claim 42 for human administration wherein said plasma protein is derived from a human.

49. The pharmaceutical composition of claim 42 for veterinary administration wherein said plasma protein is derived from an animal other than human.

50. The pharmaceutical composition of claim 42, wherein said plasma protein is a component of natural plasma or a recombinant plasma protein.

51. The pharmaceutical composition of claim 42, wherein the plasma protein is selected from the group consisting of human serum albumin, animal serum

albumin, recombinant human serum albumin, recombinant animal serum albumin, γ-globulin, and recombinant γ-globulin.

52. The pharmaceutical composition of claim 42, wherein the plasma protein is selected from a group consisting of immunoglubulin, glycoprotein, interferon, interleukin, and recombinant immunoglubulin, glycoprotein, interferon, and interleukin.

53. The pharmaceutical composition of claim 42, wherein said therapeutically active compound is selected from the group consisting of a cytostatic, an antibiotic, a vitamin, an anti-inflammatory, an analgesic, an antiviral, an anticonvulsant, an immunosupressant, an antiepileptic, an anxiolytic, a hynotic, an antifungal agent, an anticoagulant, a lipid peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, an uricosuric, an antithrombotic, a steroid hormone (progestogen, androgen, testogen) and a photosensitizer and the plasma protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

54. The pharmaceutical composition of claim 42, wherein said therapeutically active compound is selected from the group consisting of a cytostatic, an antibiotic, a vitamin, an anti-inflammatory, an analgesic, an antiviral, an anticonvulsant, an

immunosupressant, an antiepileptic, an anxiolytic, a hynotic, an antifungal agent, an anticoagulant, a lipid peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, an uricosuric, an antithrombotic, a steroid hormone (progestogen, androgen, testogen) and a photosensitizer and the plasma protein is selected from the group consisting of immunoglublin, glycoprotein, interferon, and interleukin and recombinant immunoglublin, glycoprotein, interferon, interleukin.

55. The pharmaceutical composition of claim 42 wherein said therapeutically active compound is selected from the group consisting of amphotericin B, an adriamicine analogue, apazone, azathiprine, bromazepam, camptothecin, carbamazepine, clonazepam, cyclosporine A, diazepam, dicumarol, digitoxine, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, xetoconazole, miconazole, niflumic acid, oxazepam, phenobarbital, phenytoin, progesterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, tesosterone, tirilazad, trioxsalen, valproic acid, warfarin and the plasma protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

56. The pharmaceutical composition of claim 42 wherein said active compound is selected from the group consisting of amphotericin B, an adriamicine analogue,

apazone, azathiprine, bromazepam, camptothecin, carbamazepine, clonazepam, cyclosporine A, diazepam, dicumarol, digitoxine, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, xetoconazole, miconazole, niflumic acid, oxazepam, phenobarbital, phenytoin, progesterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, tesosterone, tirilazad, trioxsalen, valproic acid, warfarin and the plasma protein is selected from the group consisting of immunoglublin, glycoprotein, interferon, and interleukin and recombinant immunoglublin, glycoprotein, interferon, and interleukin.

57. The pharmaceutical composition of claim 45 comprising a taxonoid of the formula



wherein R^1 is tertiary butyl-oxy-carboxylic acid amide or benzoyl amide, R^2 is hydrogen or an acyl group.

58. The pharmaceutical composition of claim 57 wherein said acyl group is an acetyl group.

59. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is paclitaxel.

60. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is paclitaxel.

61. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is amphothericin B.

62. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is amphothericin B.

63. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is gemfibrozil.

64. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is gemfibrozil.

65. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is miconazole.

66. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is miconazole.

67. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is propofol.

68. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is propofol.

69. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is tamoxifen.

70. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is tamoxifen.

71. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is ritonavir.

72. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is ritonavir.

73. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is tacrolimus.

74. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is tacrolimus.

75. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is tirilazad.

76. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is tirilazad.

77. The pharmaceutical composition of claim 51 wherein said therapeutically active compound is trioxsalen.

78. The pharmaceutical composition of claim 52 wherein said therapeutically active compound is trioxsalen.

79. The pharmaceutical composition of claim 45 wherein said additive is selected from the group consisting of sodium chloride, a buffer, a poly-alcohol and a water-soluble sugar derivative.

80. The pharmaceutical composition of claim 63 wherein said additive is selected from the group consisting of glycerol, mannitol, sorbitol, and dulcitol.

81. A homogeneous, solid, water-soluble product consisting essentially of at least one therapeutically active compound having an aqueous solubility of less than 1.10^{-4} M selected of the group consisting of amphotericin B, an adriamicine analogue, apazone, azathioprine, broman adriamicine analogue, apazone, azathioprine, bromazepam, camptothecin, carbamazepine, clonazepam, cyclosporine A, diazepam, dicumarol, digitoxine, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconazole, miconazole, niflumic acid, oxazepam, phenobarbital, phenytoin, progesterone, propofol, ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid and warfarin, and at least one protein selected from the group consisting of natural and recombinant serum albumin and γ-

globulin wherein the said therapeutically active compound and the said protein are non-covalently bound, and wherein the molar ratio of said therapeutically active compound to said protein is in the range of 1.0 : 0.05 to 1: 100.

82. A homogeneous, solid, water-soluble product according to claim 81 wherein the protein is selected from the group glycoprotein, interferon, interleukin and recombinant glyoprotein, interferon, interleukin.

83. A homogeneous, solid, water-soluble product according to claim 81 wherein the molar ratio of said therapeutically active compound to said protein is in the range of 1:0 :01 to 1 : 50.

84. A homogeneous, solid, water-soluble product according to claim 81 wherein said therapeutically active compound is a taxonoid of the formula



wherein R^{1is} tertiary butyl-oxy-carboxylic acid amide or benzoyl amide, R^2 is hydrogen, an acyl or an acetyl group.

85. A homogeneous, solid, water-soluble product according to claim 81 wherein said therapeutically active compound is paclitaxel and said plasma protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

86. A homogeneous, solid, water-soluble product according to claim 69 wherein said therapeutically active compound is amphotericin-B and said plasma protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

87. A homogeneous, solid, water-soluble product according to claim 69 wherein said active compound is camptothecin and said protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

88. A homogeneous, solid, water-soluble product according to claim 69 wherein said therapeutically active compound is cyclosporin A and said protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

89. A homogeneous, solid, water-soluble product according to claim 69 wherein said therapeutically active compound is propofol and said plasma protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

90. A homogeneous, solid, water-soluble product according to claim 69 wherein said therapeutically active compound is propofol and said protein is selected from the group consisting of natural and recombinant serum albumin and γ-globulin.

91. A method of treating a human or veterinary patient in need thereof with the pharmaceutical composition of claim 1, comprising the step of administering an effective amount of said pharmaceutical composition to the patient.